Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1865,2-1,55
Msft2,10
Nokia4,30054,351-1,19
IBM-0,42
Mercedes-Benz Group AG68,1168,130,63
PFE1,40
01.02.2023 2:04:00
Indexy online
AD Index online
select
AD Index online
 

Biogen Idec
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.02.2023
Popis společnosti
Obecné informace
Název společnostiBiogen Inc
TickerBIIB
Kmenové akcie:Ordinary Shares
RICBIIB.O
ISIN-
Prioritní akciePreference Shares Series A
Prioritní akciePreference Shares Series X
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.12.2021 9 610
Akcie v oběhu k 24.10.2022 144 001 404
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice225 Binney Street
MěstoCAMBRIDGE
PSČ02142
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 814 642 000
Fax13026365454

Business Summary: Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Biogen Inc revenues decreased 7% to $7.63B. Net income increased from $1.19B to $2.5B. Revenues reflect Rest of World segment decrease of 9% to $3.46B, United States segment decrease of 8% to $2.62B. Net income reflects Impairment of Intangibles Excl Goodwill decrease from $629.3M (expense) to $0K, FV Adjustments of Financial Investments decrease of 78% to $158.1M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biopharmaceuticals
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 01.02.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorChristopher Viehbacher6214.11.202214.11.2022
Chief Financial Officer, Executive Vice PresidentMichael McDonnell5815.08.202015.08.2020
Chief Human Resource Officer, Executive Vice PresidentGinger Gregory5417.07.201717.07.2017
Executive Vice President, Chief Legal Officer and SecretarySusan Alexander6530.01.2006
Executive Vice President, Pharmaceutical Operations and TechnologyAlphonse Galdes6901.10.201901.10.2019
Executive Vice President, Head of Alzheimers Disease and Dementia Business UnitRachid Izzar47
Executive Vice President - Head of DevelopmentPriya Singhal-05.01.202305.01.2023
Senior Vice President, Chief Accounting OfficerRobin Kramer5619.11.2018